Revelation Biosciences, Inc. (NASDAQ:REVB) Sees Significant Growth in Short Interest

Revelation Biosciences, Inc. (NASDAQ:REVB) was the recipient of a large growth in short interest during the month of February. As of February 15th, there was short interest totalling 89,500 shares, a growth of 41.2% from the January 31st total of 63,400 shares. Based on an average daily trading volume, of 223,600 shares, the short-interest ratio is presently 0.4 days. Approximately 17.1% of the shares of the company are short sold.

Revelation Biosciences Price Performance

Shares of NASDAQ REVB traded up $0.10 during trading on Wednesday, reaching $3.55. 8,395 shares of the stock traded hands, compared to its average volume of 102,733. Revelation Biosciences has a 52-week low of $3.19 and a 52-week high of $60.80. The company has a 50-day moving average of $5.55 and a 200-day moving average of $10.33. The stock has a market capitalization of $950,060.00, a P/E ratio of -0.01 and a beta of 0.17.

Revelation Biosciences Company Profile

Revelation Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease.